Unity Biotechnology Inc. has raised $116m in Series B venture capital to go after a different set of problems associated with aging than the company’s top executives tackled with their prior company Kythera Biopharmaceuticals Inc.
Kythera, which new Unity CEO Keith Leonard sold to Allergan PLC last year for $2.1bn, developed Kybella (deoxycholic acid) to reduce the appearance of a double chin. Unity was formed to develop drugs that target senescent cells in hopes of helping people live better and potentially longer lives